Literature DB >> 10813127

ras p21 Isoprenylation inhibition induces flat colon tumors in Wistar rats.

H Iishi1, M Tatsuta, M Baba, H Yano, N Sakai, H Uehara, A Nakaizumi.   

Abstract

PURPOSE: The effect of pravastatin, an inhibitor of ras p21 isoprenylation, on the gross type of colon tumors induced by azoxymethane was investigated in Wistar rats.
METHODS: Rats received ten weekly subcutaneous injections of 7.4 mg/kg body weight of azoxymethane and intraperitoneal injections of 10 or 20 mg/kg body weight of pravastatin every other day until the end of the experiment at Week 45.
RESULTS: Administration of pravastatin at both dosages had no significant effect on the incidence of colon tumors but significantly increased the incidence of rats with adenomas only. In contrast to the elevated adenomas in control rats, flat adenomas were significantly more prevalent in rats given pravastatin. Pravastatin at both doses significantly decreased the labeling index, but not the apoptotic index, of elevated adenomas, whereas it significantly decreased the labeling index but increased the apoptotic index of flat adenomas. Administration of pravastatin at both dosages also significantly decreased the amounts of membrane-associated ras p21 in colon tumors.
CONCLUSIONS: These findings suggest that the ras oncogene may be closely related to the development of adenocarcinomas from adenomas and the development of elevated or polypoid tumors of the colon.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10813127     DOI: 10.1007/bf02237247

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  3 in total

Review 1.  Statin therapy in cardiovascular diseases other than atherosclerosis.

Authors:  Dominique Beaudry; Kenneth E Stone; Suzanne Wetherold; John Hemphill; Dat Do; John McClish; Robert Chilton
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

2.  Prevalence and distribution of adenomas in black Americans undergoing colorectal cancer screening.

Authors:  Frank K Friedenberg; Mandeep Singh; Nina S George; Abhinav Sankineni; Swetang Shah
Journal:  Dig Dis Sci       Date:  2011-11-04       Impact factor: 3.199

3.  Ezetimibe is an inhibitor of tumor angiogenesis.

Authors:  Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.